To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Directorate change

Release Date: 15/11/2018 09:01
Code(s): MEI     PDF:  
Wrap Text
Directorate change

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)

15 November 2018

DIRECTORATE CHANGE

The Company announces that on 14 November 2018, Mr Desmond Smith, the Company’s Senior
Independent Director, informed the Board of his intention to retire as a director of the Company at the
conclusion of the Company’s Annual General Meeting (“AGM”) scheduled for 24 July 2019 and not
seek re-election at the AGM. Mr Smith will also step down from all Board committees at that time.

Mr Alan Grieve will succeed Mr Smith as Senior Independent Director of the Company and as Chairman
of the Audit and Risk Committee, to be effective from the date of Mr Smith’s resignation in 2019.

Further changes to the constitution of the Company’s committees will be made and announced in due
course.

Mediclinic's chairman, Dr Edwin Hertzog commented:
“On behalf of my colleagues on the Board, I would like to thank Desmond for his commitment and
valued contributions to the Board and the Group over many years.”

This announcement is made in accordance with the requirement of LR 9.6.11.

About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in Switzerland,
Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to
enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary
healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed
and UK-based private healthcare group.

Mediclinic comprises 76 hospitals and 30 clinics. Hirslanden operates 18 private hospitals and 4 clinics
in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates 48 hospitals
and 4 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient
beds in total; and Mediclinic Middle East operates 7 hospitals and 22 clinics with more than 900 inpatient
beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary
listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 15/11/2018 09:01:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story